NEW YORK (GenomeWeb) – Foundation Medicine's stockholders today approved Roche's pending offer to take a majority stake in the company.

In a special meeting, shareholders of the Cambridge, Mass.-based cancer molecular diagnostics firm voted in favor of all the proposals related to the Roche transaction, which included its offer to purchase up to 15.6 million shares of Foundation Medicine stock for $50 per share and an additional 5 million newly issued shares for $50 per share, as well as commitments to invest in R&D.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.